# Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Study · id `cardio:ct-nct06813911` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06813911](<https://clinicaltrials.gov/study/NCT06813911>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06813911

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 246 participants.

## Technical summary

Registry record NCT06813911. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2028-02-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 246 participants (enrolled count; ClinicalTrials.gov record NCT06813911, source copy `cardio:ctgov-nct06813911-2026-10-14`, retrieved 2026-10-31)
- Started: 2025-04-30 (actual) (ClinicalTrials.gov record NCT06813911, source copy `cardio:ctgov-nct06813911-2026-10-14`, retrieved 2026-10-31)
- Primary completion: 2028-02-03 (anticipated) (ClinicalTrials.gov record NCT06813911, source copy `cardio:ctgov-nct06813911-2026-10-14`, retrieved 2026-10-31)
- Completion: 2028-02-29 (anticipated) (ClinicalTrials.gov record NCT06813911, source copy `cardio:ctgov-nct06813911-2026-10-14`, retrieved 2026-10-31)
- Countries: United States; China; France; Germany; Hong Kong SAR China; Italy; Netherlands; Puerto Rico; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06813911, source copy `cardio:ctgov-nct06813911-2026-10-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06813911-2026-10-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Acronym: ADD-VANTAGE
- Condition: Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug): Pelacarsen
- Intervention (Drug): Placebo
- Intervention (Drug): Inclisiran
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 41f9a25dc591cbd30f5d930f81e17b64a531ad12fe660f5488cff40484705e62
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
